pyrazines has been researched along with oprozomib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kay, LE; Ruschak, AM; Schimmer, AD; Slassi, M | 1 |
| Appel, A | 1 |
| Al, M; Assaraf, YG; Chan, ET; de Gruijl, TD; den Uyl, D; Dijkmans, BA; Jansen, G; Kirk, CJ; Oerlemans, R; Peters, GJ; Scheffer, GL; Scheper, RJ; van der Heijden, JW; Verbrugge, SE | 1 |
| Chan, ET; DeLancey, HM; Freilino, ML; Grandis, JR; Johnson, DE; Kirk, CJ; Li, C; Thomas, SM; Zang, Y | 1 |
| Hu, Y; Wu, P; Zhang, J | 1 |
| Anderl, J; Gupta, S; Kirk, C; Kruger, WD; Slifker, MJ; Wang, L | 1 |
| Claas, FH; Heidt, S; Mulder, A; Roelen, DL; Vergunst, M | 1 |
| Johnson, DE; Kirk, CJ; Zang, Y | 1 |
2 review(s) available for pyrazines and oprozomib
| Article | Year |
|---|---|
Novel proteasome inhibitors to overcome bortezomib resistance.
Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chloroquine; Clioquinol; Drug Resistance, Neoplasm; Humans; Hydroxyquinolines; Lactones; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Threonine; Ubiquitinated Proteins; Ubiquitination | 2011 |
Clinical and marketed proteasome inhibitors for cancer treatment.
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine | 2013 |
1 trial(s) available for pyrazines and oprozomib
| Article | Year |
|---|---|
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with
Topics: Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Leukocytes, Mononuclear; Mutation; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2012 |
5 other study(ies) available for pyrazines and oprozomib
| Article | Year |
|---|---|
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
Topics: Activating Transcription Factor 4; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Head and Neck Neoplasms; Humans; Models, Biological; Oligopeptides; Proteasome Inhibitors; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Unfolded Protein Response | 2012 |
Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.
Topics: Animals; Boronic Acids; Bortezomib; Cystathionine beta-Synthase; Female; Homocystinuria; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation, Missense; Oligopeptides; Proteasome Inhibitors; Protein Folding; Pyrazines | 2013 |
Proteasome inhibition profoundly affects activated human B cells.
Topics: Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Humans; Immunoglobulin G; Immunoglobulin M; In Vitro Techniques; Oligopeptides; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines | 2013 |
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mitochondrial Proteins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Vorinostat | 2014 |